Cargando…
Development of cell-cycle inhibitors for cancer therapy
The cell cycle governs the transition from quiescence through cell growth to proliferation. The key parts of the cell cycle machinery are the cyclin-dependent kinases (cdks) and the regulatory proteins called cyclins. The cdks are rational targets for cancer therapy because their expression in cance...
Autores principales: | Dickson, M.A., Schwartz, G.K. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Multimed Inc.
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669234/ https://www.ncbi.nlm.nih.gov/pubmed/19370178 |
Ejemplares similares
-
Novel developments in angiogenesis cancer therapy
por: Hirte, H.W.
Publicado: (2009) -
Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008) -
rna interference and micro rna –oriented therapy in cancer: rationales, promises, and challenges
por: Duchaine, T.F., et al.
Publicado: (2009) -
Small-molecule Bcl-2 antagonists as targeted therapy in oncology
por: Warr, M.R., et al.
Publicado: (2008) -
Targeting mtor-dependent tumours with specific inhibitors: a model for personalized medicine based on molecular diagnoses
por: Furic, L., et al.
Publicado: (2009)